Food and Drug Administration advisory panel votes 10 to 6 against approval of Qnexa, new weight-loss drug developed by Vivus; final decision by FDA on drug will be issued in October; ruling is consistent with FDA track record of exercising caution when approving obesity drugs, which have history of safety problems; Onexa is noted to have some serious potential side effects like depression or suicidal thinking, increased heart rate and possible birth defects; Vivus argues that being obese carrie…
View full news here NYT > Weight
